The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Goetz, C. G., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stebbins, G. T., Stern, M. B., Tilley, B. C., Dodel, R., Dubois, B., et al. (2007) · Movement Disorders · doi:10.1002/mds.21198 · Cited by 1,404
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Self-citationNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fenelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,037
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Self-citationSerotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Self-citationLow-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
(1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401003 · Cited by 615
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., et al. (2007) · Movement Disorders · doi:10.1002/mds.21382 · Cited by 528
Self-citationMiyasaki, J. M., Shannon, K., Voon, V., Ravina, B., Kleiner-Fisman, G., Anderson, K., Shulman, L. M., Gronseth, G., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215428.46057.3d · Cited by 487
Lewis, J. A. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990815)18:15<1903::aid-sim188>3.0.co;2-f · Cited by 413
Kuroki, T., Meltzer, H. Y., & Ichikawa, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38019-x · Cited by 351
Self-citation(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1444 · Cited by 339
Meltzer, H. Y., Arvanitis, L., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330
Self-citationHallucinations in Parkinson disease
Diederich, N. J., Fénelon, G., Stebbins, G., & Goetz, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.62 · Cited by 312
Ondo, W. G., Tintner, R., Dat Voung, K., Lai, D., & Ringholz, G. (2005) · Movement Disorders · doi:10.1002/mds.20474 · Cited by 297
Rabey, J. M., Prokhorov, T., Miniovitz, A., Dobronevsky, E., & Klein, C. (2007) · Movement Disorders · doi:10.1002/mds.21116 · Cited by 259
Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
Goetz, C. G., Blasucci, L. M., Leurgans, S., & Pappert, E. J. (2000) · Neurology · doi:10.1212/wnl.55.6.789 · Cited by 249
Aminergic systems in Alzheimer's disease and Parkinson's disease
D'Amato, R. J., Zweig, R. M., Whitehouse, P. J., Wenk, G. L., Singer, H. S., Mayeux, R., Price, D. L., & Snyder, S. H. (1987) · Annals of Neurology · doi:10.1002/ana.410220207 · Cited by 248
Longitudinal outcome of Parkinson’s disease patients with psychosis
Factor, S. A., Feustel, P. J., Friedman, J. H., Comella, C. L., Goetz, C. G., Kurlan, R., Parsa, M., Pfeiffer, R., & the Parkinson Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000068010.82167.cf · Cited by 234
Self-citationClozapine in drug-induced psychosis in Parkinson's disease
(1999) · The Lancet · doi:10.1016/s0140-6736(99)00860-0 · Cited by 230
Prisco, S., Pagannone, S., & Esposito, E. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22843-9 · Cited by 214
Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis
Morgante, L., Epifanio, A., Spina, E., Zappia, M., Di Rosa, A. E., Marconi, R., Basile, G., Di Raimondo, G., La Spina, P., & Quattrone, A. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000136891.17006.ec · Cited by 214
5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease
Holmes, C. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.9.1507 · Cited by 204
Vanover, K. E., Weiner, D. M., Makhay, M., Veinbergs, I., Gardell, L. R., Lameh, J., Del Tredici, A. L., Piu, F., Schiffer, H. H., Ott, T. R., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097006 · Cited by 204
Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
Fernandez, H. H., Friedman, J. H., Jacques, C., & Rosenfeld, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199905)14:3<484::aid-mds1016>3.0.co;2-b · Cited by 193
Self-citationScales to assess psychosis in Parkinson's disease: Critique and recommendations
Fernandez, H. H., Aarsland, D., Fénelon, G., Friedman, J. H., Marsh, L., Tröster, A. I., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., et al. (2008) · Movement Disorders · doi:10.1002/mds.21875 · Cited by 188
Self-citationReynolds, G. P., Mason, S. L., Meldrum, A., De Keczer, S., Parties, H., Eglen, R. M., & Wong, E. H. F. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13303.x · Cited by 180
Prospective longitudinal assessment of hallucinations in Parkinson’s disease
Goetz, C. G., Leurgans, S., Pappert, E. J., Raman, R., & Stemer, A. B. (2001) · Neurology · doi:10.1212/wnl.57.11.2078 · Cited by 178
Localization of 5-HT2A receptors on dopamine cells in subnuclei of the midbrain A10 cell group
Nocjar, C., Roth, B. L., & Pehek, E. A. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00593-0 · Cited by 171
Schmidt, C. J., Fadayel, G. M., Sullivan, C. K., & Taylor, V. L. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90819-p · Cited by 162
Early dopaminergic drug-induced hallucinations in parkinsonian patients
Goetz, C. G., Vogel, C., Tanner, C. M., & Stebbins, G. T. (1998) · Neurology · doi:10.1212/wnl.51.3.811 · Cited by 156
Rater-blinded, Prospective Comparison
Merims, D., Balas, M., Peretz, C., Shabtai, H., & Giladi, N. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000236769.31279.19 · Cited by 156
Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro
Pessia, M., Jiang, Z., North, R. A., & Johnson, S. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90495-2 · Cited by 150
Psychiatric Complications in Parkinson Disease
Weintraub, D. A., & Stern, M. B. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.10.844 · Cited by 149
An overview of side effects caused by typical antipsychotics.
Arana, G. W. (2000) · PubMed · Cited by 147
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
Shotbolt, P. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5335 · Cited by 144
Assal, F., Alarcón, M., Solomon, E., Masterman, D. L., Geschwind, D. H., & Cummings, J. L. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1249 · Cited by 142
Psychotic symptoms in Parkinson’s disease: From description to etiology
Papapetropoulos, S., & Mash, D. C. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0918-5 · Cited by 136
O‘Neill, M. F., Heron-Maxwell, C., & Shaw, G. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00240-8 · Cited by 134
Pehek, E. A., McFarlane, H. G., Maguschak, K. A., Price, B., & Pluto, C. P. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03004-3 · Cited by 131
Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine
KESSLER, R. M., Ansari, M. S., Riccardi, P., Li, R., Jayathilake, K., Dawant, B. M., & Meltzer, H. Y. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301108 · Cited by 128
Self-citationTreatment of Psychosis in Parkinson???s Disease: Safety Considerations
Fernandez, H. H., Trieschmann, M. E., & Friedman, J. H. (2003) · Drug Safety · doi:10.2165/00002018-200326090-00004 · Cited by 123
Self-citationFriedberg, G., Zoldan, J., Weizman, A., & Melamed, E. (1998) · PubMed · Cited by 120
Reddy, S., Factor, S. A., Molho, E., & Feustel, P. J. (2002) · Movement Disorders · doi:10.1002/mds.10176 · Cited by 113
High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET
Nordström, A., Farde, L., & Halldin, C. (1993) · Psychopharmacology · doi:10.1007/bf02251294 · Cited by 102
The Management of the Levodopa Psychoses
Friedman, J. H. (1991) · Clinical Neuropharmacology · doi:10.1097/00002826-199108000-00001 · Cited by 94
Self-citation[Psychotic symptoms in Parkinson's disease].
Fénelon, G. (2006) · PubMed · Cited by 92
Waeber, C., & Palacios, J. M. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90082-1 · Cited by 86
Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis
Frieling, H., Hillemacher, T., Ziegenbein, M., Neundörfer, B., & Bleich, S. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.08.007 · Cited by 78
Vanover, K. E., Betz, A. J., WEBER, S., Bibbiani, F., Kielaitė, A., Weiner, D. M., DAVIS, R., Chase, T. N., & Salamone, J. D. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.04.010 · Cited by 78
Yan, Q. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00208-7 · Cited by 77
Worsening of motor features of Parkinsonism with olanzapine
Molho, E., & Factor, S. A. (1999) · Movement Disorders · doi:10.1002/1531-8257(199911)14:6<1014::aid-mds1017>3.0.co;2-9 · Cited by 77
Pritchard, A. L., Harris, J. M., Pritchard, C. W., Coates, J., Haque, S. M., HOLDER, R. L., Bentham, P., & Lendon, C. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.011 · Cited by 70
Post‐Synaptic 5‐HT1A and 5‐HT2A Receptors Are Increased in Parkinson's Disease Neocortex
Chen, C., ALDER, J. T., Bray, L., Kingsbury, A. E., Francis, P. T., & Föster, O. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10229.x · Cited by 69
Psychosis in Parkinson’s Disease
Wint, D. P., Okun, M. S., & Fernandez, H. H. (2004) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704267457 · Cited by 65
5-HT1B receptor binding in degenerative movement disorders
Castro, E., Pascual, J., Romón, T., Berciano, J., Figols, J., & Pazos, Á. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01566-7 · Cited by 64
Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease
Meltzer, H. Y., Kennedy, J., Dai, J., Parsa, M., & Riley, D. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00060-d · Cited by 60
Self-citation5‐HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease
LAM, L. C. W., Tang, N. L. S., Ma, S. L., Zhang, W., & Chiu, H. F. K. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1109 · Cited by 57
Pressler, M., Nopoulos, P., Ho, B., & Andreasen, N. C. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.010 · Cited by 54
Rationale for current therapies in Parkinson?s disease
Romrell, J., Fernandez, H. H., & Okun, M. S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.10.1747 · Cited by 52
Central D1- and D2-receptor occupancy during antipsychotic drug treatment
Wiesel, F., Farde, L., Nordström, A., & Sedvall, G. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90046-j · Cited by 49
Morphometry of the Superior Temporal Plane In Schizophrenia: Relationship to Clinical Correlates
Crespo‐Facorro, B., Kim, J., Chemerinski, E., Magnotta, V. A., Andreasen, N. C., & Nopoulos, P. (2004) · Journal of Neuropsychiatry · doi:10.1176/jnp.16.3.284 · Cited by 35
Mancini, F., Tassorelli, C., Martignoni, E., Moglia, A., Nappi, G., Cristina, S., & Pacchetti, C. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200401000-00010 · Cited by 31
PD-related psychosis: pathophysiology with therapeutical strategies
Wolters, E. C. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_4 · Cited by 27
The management of psychosis in movement disorder patients
Chou, K. L., Borek, L. L., & Friedman, J. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.935 · Cited by 23
Self-citation
Cited by
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., & Ballard, C. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
Self-citationTherapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Update on Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050911-161504 · Cited by 433
Self-citation
Metadata
- Authors
- Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H.
- Venue
- Neuropsychopharmacology
- Published
- 2009-11-11
- Volume
- 35
- Issue
- 4
- Pages
- 881-892
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1967630951
- Cited by
- 292
- References
- 73
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.